Last 21.50 NOK
Change Today 0.00 / 0.00%
Volume 0.0
PHO On Other Exchanges
Symbol
Exchange
OTC US
Oslo
Stuttgart
As of 10:25 AM 07/21/14 All times are local (Market data is delayed by at least 15 minutes).

photocure asa (PHO) Snapshot

Open
21.80 NOK
Previous Close
21.50 NOK
Day High
21.80 NOK
Day Low
21.50 NOK
52 Week High
08/6/13 - 41.60 NOK
52 Week Low
12/27/13 - 21.10 NOK
Market Cap
460.0M
Average Volume 10 Days
4.3K
EPS TTM
-2.36 NOK
Shares Outstanding
21.4M
EX-Date
05/23/13
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHOTOCURE ASA (PHO)

Related News

No related news articles were found.

photocure asa (PHO) Related Businessweek News

No Related Businessweek News Found

photocure asa (PHO) Details

Photocure ASA is engaged in the research, development, production, distribution, marketing, and sale of pharmaceutical products and related technical medical equipment. It operates through Cancer and Dermatology segments. The company markets Hexvix/Cysview for the detection of bladder cancer. Its products pipeline includes Visonac that has completed phase IIb study for the treatment of moderate to severe acne; Cevira, which is under phase IIb study for the treatment of human papilloma virus disease and precancerous lesions of the cervix; and Lumacan that is under phase I/II development for the detection of colorectal cancer. The company sells its products to license partners, pharmaceutical wholesalers, and hospitals. It has strategic agreement with Salix Pharmaceuticals Inc. for the development and commercialization of Lumacan. The company operates in Norway, Sweden, Denmark, Finland, and the United States. Photocure ASA was founded in 1997 and is headquartered in Oslo, Norway.

50 Employees
Last Reported Date: 04/30/14
Founded in 1997

photocure asa (PHO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

photocure asa (PHO) Key Developments

PhotoCure ASA Reports Earnings Results for the First Quarter Ended Mar. 31, 2014

PhotoCure ASA reported earnings results for the first quarter ended Mar. 31, 2014. For the quarter, the company reported total revenues of NOK 20.7 million against NOK 15.7 million for the same period a year ago. Operating loss excluding restructuring & one-off was NOK 13.7 million against NOK 23.6 million for the same period a year ago. Operating loss including non-recurring was NOK 13.7 million against NOK 23.6 million for the same period a year ago. Net loss for continued operations was NOK 13 million or NOK 0.61 per diluted share against NOK 21.4 million or NOK 1.01 per diluted share for the same period a year ago. Total sales revenues of Hexvix/Cysview increased 33% to NOK 19.3 million against NOK 14.5 million for the same period a year ago, driven by strong underlying customer demand and wlume growth in the major markets, Hexvix/Cysview global in-market sales value growth of 36% in the quarter to NOK 46 million.

PhotoCure ASA, Q1 2014 Earnings Call, May 07, 2014

PhotoCure ASA, Q1 2014 Earnings Call, May 07, 2014

PhotoCure ASA Reports Audited Consolidated and Parent Earnings Results for the Year Ended December 31, 2013

PhotoCure ASA reported audited consolidated and parent earnings results for the year ended December 31, 2013. For the year, on parent basis, the company reported sales revenue of NOK 64,224,000 against NOK 85,410,000 a year ago. Total revenues were NOK 68,533,000 against NOK 144,151,000 a year ago. Operating loss recurring was NOK 48,498,000 against NOK 911,000 a year ago. Loss before tax was NOK 35,305,000 against profit before tax of NOK 2,637,000 a year ago. Net loss for continued operations was NOK 27,036,000 against net profit for continued operations of NOK 3,527,000 a year ago. Net loss for the year was NOK 27,036,000 against NOK 4,981,000 a year ago. Net cash flow used in operating activities was NOK 16,021,000 against NOK 40,932,000 a year ago. Investments in machinery and equipment were NOK 1,085,000 against NOK 906,000 a year ago. For the year, on consolidated basis, the company reported sales revenue of NOK 79,307,000 against NOK 75,082,000 a year ago. Total revenues were NOK 83,616,000 against NOK 133,823,000 a year ago. Operating loss recurring was NOK 71,846,000 against NOK 39,248,000 a year ago. Loss before tax was NOK 66,852,000 against NOK 31,012,000 a year ago. Net loss for continued operations was NOK 58,648,000 against NOK 30,122,000 a year ago. Net loss for the year was NOK 58,950,000 against NOK 47,901,000 a year ago. Diluted loss per share was NOK 2.77 against NOK 2.24 a year ago. Diluted loss per share continued operations was NOK 2.75 against NOK 1.41 a year ago. Net cash flow used in operating activities was NOK 99,722,000 against NOK 54,928,000 a year ago. Investments in machinery and equipment were NOK 1,155,000 against NOK 1,309,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PHO:NO 21.50 NOK 0.00

PHO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PHO.
View Industry Companies
 

Industry Analysis

PHO

Industry Average

Valuation PHO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.1x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHOTOCURE ASA, please visit www.photocure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.